UNSPSC 51372041: Nalfurafine hydrochloride

This classification denotes an opioid receptor agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 25CC4N0P8J. European Medicines Agency schedules Nalfurafine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32294. Nalfurafine hydrochloride generally arises in the molecular formula C28H32N2O5.CLH. The term 'nalfurafine hydrochloride' is a United States Adopted Name designation.

Most nations, for tariff and trade purposes, schedule nalfurafine hydrochloride under HS 29391900 and SITC 54141. As of Q4 2014, NALFURAFINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Nalfurafine hydrochloride bears US NLM identifiers UMLS ID C1610428 and NCI Concept Code C80586. SMILES: CN([C@@H]1CC[C@]2([C@H]3CC4CCC(C5C4[C@]2([C@H]1O5)CCN3CC6CC6)O)O)C(=O)/C=C/C7CCOC7.CL.

UNSPSC 51372041 Nalfurafine hydrochloride is a Commodity code that in practice captures state and local procurement of pharmaceutical products and drug-related systems, though recent solicitations tagged under it show limited specificity to nalfurafine itself and instead reflect broader pharmacy procurement activity. State and local governments are using this code to source naloxone and safe drug deactivation systems for community health initiatives, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing agreements, and direct-to-manufacturer prescription fulfillment capabilities. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving participating states including Oregon and Minnesota). The procurement spans health and pharmacy benefit administration across counties, state agencies, and cooperatively-purchasing local government facilities.

Recent activity is concentrated in Florida, Texas, and Minnesota. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due by July 26, 2023; the contract carries a two-year initial term with one-year renewal option and requires E-Verify compliance, drug-free workplace certification, and potential FEMA funding compliance. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, gathering vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to support direct contracting outside traditional pharmacy benefit manager and group purchasing organization channels, with no formal award timeline established in the exploratory phase. Minnesota's MMCAP issued RFP S1070000015802 on January 20, 2026, due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson), with contract effectiveness July 1, 2026, and evaluation weighted 75 percent on price competitiveness, requiring cGMP and Drug Supply Chain Security Act compliance.